JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH最新文献

{"title":"Association of Dental Pulp Stem Cells and Ricinus Bone Compound in a Model of Bone Defect","authors":"Alan Araújo de Jesus, A. Jesus, Flávia Oliveira de Lima, Luíz A. R. Freitas, Cassio S Meira, R. Ribeiro-dos-Santos, M. Soares","doi":"10.34178/jbth.v3i3.129","DOIUrl":"https://doi.org/10.34178/jbth.v3i3.129","url":null,"abstract":"Autogenous bone grafting is needed in some bone tissue defects; however, it causes secondary surgical wounds and morbidity. Tissue bioengineering may be an alternative approach for bone regeneration. Here we investigated the osteogenic potential of dental pulp stem cells from deciduous teeth (DPSC) in association with a Ricinus bone compound (RBC) in a model of bone defect. The influence of the biomaterial RBC on the proliferation and osteogenic differentiation of DPSC was assessed in vitro by MTT metabolism and alizarin red staining, respectively. The morphologic analysis was performed using the optic and scanning electron (SEM) microscopies. For the in vivo study, 54 Wistar rats submitted to calvarial defects were filled with RBC or RBC+DPSC. A control group had the defects filled only with blood clots. Analyses were performed 15, 30 and 60 days after treatment using digital radiography, optical microscopy, SEM and chemical analysis by electron dispersive spectroscopy. The Ricinus bone compound (RBC) did not inhibit the osteogenic differentiation in vitro. No spontaneous regeneration was observed in the control group. The area of the calvarial defect of the RBC+DPSC group showed greater radiopacity on day 15. The RBC presented no reabsorption, was biocompatible and showed osteointegration, working as a mechanical filling. Only sparse ossification areas were found and those were larger and more developed on the RBC+DPSC group when compared to animals treated only with RBC. RBC in association with DPSC is a promising combination for applications in bone regeneration. \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125808920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccines’ Candidates Against SARS-CoV-2","authors":"ISI-SENAI-CIMATEC Group, Development and Innovation Laboratory of Butantan ","doi":"10.34178/jbth.v3i2.126","DOIUrl":"https://doi.org/10.34178/jbth.v3i2.126","url":null,"abstract":"Scientists, health organizations, and pharmaceutical companies are making a large global effort to develop vaccines against SARS-CoV-2, the virus of COVID-19 since the outbreak began. Until now, we have more than 150 candidates. However, 19 vaccine candidates have entered clinical trials in phase 2 and 3 trials (31 July 2020). In this article we aimed to present the platforms for COVID-19 vaccine, the types of vaccines (live, attenuated, inactivated, DNA/RNA, proteins subunits, viral vector), the antigen selection, adjuvants, and we focused on the phase 2/3 trial vaccines at this point (Sinopharm, Coronavac, Moderna, Oxford, Biontech). We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We reviewed 216 articles and used 106 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, vaccine, platform, antigen, subunit, live and attenuated vaccine, RNA vaccine, live vaccine, inactivated vaccine, types of vaccines, adjuvants, replication, viral vector, phase 1-3, trial, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that although vaccines have shown safety in phase 1 and efficacy in phase 2 and the beginning of phase 3 is starting, the most renowned scientists believe that a vaccine will be available only in the middle of next year. \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128639368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapies Against COVID-19: a Running to a Treatment","authors":"ISI-SENAI-CIMATEC Group, Development and Innovation Laboratory of Butantan ","doi":"10.34178/jbth.v3i2.125","DOIUrl":"https://doi.org/10.34178/jbth.v3i2.125","url":null,"abstract":"There is no specific drug or therapy against COVID-19. Since the beginning of the pandemic, scientists are running to discover a drug or therapy that can treat the disease. What we found until now are a combined drug and therapies that can mitigate the effects of the disease in the human body and how to manage the patient better. In this article, we tried to join the new discoveries and presented the drugs and therapies and their mechanisms to combat the SARS-CoV-2. We showed the immunomodulators, parasiticides, antiviral drugs (focused on Remdesivir), antimalarial drugs, anti-cytokine drugs focused on the role of IL-6, Reumathological drugs, inhibitors of cell-receptors, antiinflammatory drugs, especially the role of corticosteroids (dexamethasone), antibiotics (azithromycin), anti-thrombotic drugs, blood derivates therapies and alternative therapies currently used against COVID-19. Also, we listed the main results of clinical trials of new therapies presented by Recommended Panel Treatment Guidelines [NIAID-RML (USA)]. We searched the data in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We used 302 articles from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, immunomodulators, parasiticides, antiviral, antimalarial, anti-thrombotic and anti-cytokine, antiinflammatory, Reumathological drugs, inhibitors of cell-receptors, antibiotics, blood derivates therapies and alternative therapies, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that despite there is no treatment or drugs against the COVID-19, a combined therapy can help and mitigate the effects of the disease, helping the immune system to combat the virus. \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126307200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic of COVID-19: Chest Computer Tomography or RT-PCR?","authors":"ISI-SENAI-CIMATEC Group","doi":"10.34178/jbth.v3i2.124","DOIUrl":"https://doi.org/10.34178/jbth.v3i2.124","url":null,"abstract":"In this review article, we presented a gold-standard method to detect the SARS-CoV-2, the novel virus that is causing the COVID-19 outbreak, and the use of a computer tomography (CT) method to detect the complications of the disease. We showed the controversial analysis about which method is the best to detect the disease earlier due to the COVID-19 complications. We searched the articles in the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Excerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews, and original articles in this order. We reviewed 96 articles and used 45 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-SARS-2, COVID-19, corona virus, coronaviruses, RT-PCR, computer tomography (CT), diagnostic methods, with the tools MeSH (Medical Subject Headings), AND, OR, and the characters [,“,; /., to ensure the best review topics. We concluded that chest CT plays an important role in the timely detection of lung infection abnormalities in the early phase of COVID-19 infection. However, the RT-PCR is the gold standard method to detect SARS-CoV-2. \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114832813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appendix 1: EUA Case Study Database WHO Case Study Database","authors":"ISI-SENAI-CIMATEC Group","doi":"10.34178/jbth.v3ia1.127","DOIUrl":"https://doi.org/10.34178/jbth.v3ia1.127","url":null,"abstract":"This Appendix 1 presents the clinical trials against COVID-19 registered in WHO and clinicaltrials.gov by United States of America database.","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115337437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contributions and Impacts on Health Using New Technologies and Innovative Products","authors":"L. Guarieiro, A. A. Santos","doi":"10.34178/JBTH.V4I1.146","DOIUrl":"https://doi.org/10.34178/JBTH.V4I1.146","url":null,"abstract":"This special edition of the Journal of Bioengineering and Technology Applied to Health brings a second selection of articles presented at the VI International Symposium on Innovation and Technology (SIINTEC). The SIINTEC happens since 2015. The event is annual and promoted by SENAI CIMATEC, Salvador, Bahia, Brazil. The VI SIINTEC focused on discussing challenges in science, technology, and innovation after COVID-19. \u0000  \u0000 ","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115510760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contributions and Impacts on Health Using New Technologies and Innovative Products","authors":"Lílian Lefol Nani Guarieiro, Alex Álisson Bandeira Santos","doi":"10.34178/jbth.v2i4.88","DOIUrl":"https://doi.org/10.34178/jbth.v2i4.88","url":null,"abstract":"This edition of the Journal of Bioengineering and Technology Applied to Health brings a selection of four articles presented at the V International Symposium on Innovation and Technology (SIINTEC)-2019.","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"225 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123638239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lethal Ovitrap CIMATEC: A New Trap for Arbovirus Transmitting Mosquitoes","authors":"E. Oyama, D. Mota","doi":"10.34178/jbth.v2i2.56","DOIUrl":"https://doi.org/10.34178/jbth.v2i2.56","url":null,"abstract":"A lot of countries have difficulty in combating Ae. aegypti, due to the high adaptability of this mosquito to the urban area. The National Program for Dengue Control (PNCD) is responsible for allocating the most activities to combat Ae. aegypti in districts of Brazil (basic sanitation, education, chemical control). Despite the technological advances in the 21th century, there was little social commitment with the conception of a formal device in the fight against Ae. aegypti. Senai-Cimatec developed a trap (Lethal Ovitrap CimatecTM) based on new technologies to control Aedes aegypti. So, the aim of this study was to compare the traditional traps on the market with the LOCTM trap, created \u0000by Cimatec. We performed two experiments to evaluate the performance of the traps against the mosquitoes. The tests occurred in a monitored and closed environment at the Central Laboratory of Bahia (Entomology Laboratory) (LACEN/BA). The larvae, water, and substrate for the experiment in the three containers had the same origin; three cages were kept in the entomology sector with the same conditions of temperature and humidity. The results showed that LOCTM has several advantages when compared to the traditional traps, such as: capacity to eliminate the immature forms of the vector in a few hours; entrapment and extermination of larvae and/or adults forms by asphyxiation; high lethality for mosquitoes and ability to reduce the Aedes population in an area by removing from the environment future generations of mosquitoes; installation; it is attractive to mosquitoes; no needs of weekly monitoring; no power consumption; simple manipulation and low-cost; water as a protection factor and not as a risk factor; it does not use insecticide or any toxic agent harmful to human health. So, the use of LOCTM has advantages over traditional traps, directing the biotechnology market to new solutions with low-cost, easy to handle and non-toxic to man and the environment in the fight agains Ae. aegypti","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120923678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of PPC / mBio Inc.’s Biochip Reader Integrated Circuit Reader System for Diagnosis of HIV / HCV Infection: Preliminary Method","authors":"L. Knop, R. Badaró, Chris Myat","doi":"10.34178/jbth.v2i1.49","DOIUrl":"https://doi.org/10.34178/jbth.v2i1.49","url":null,"abstract":"The technological advances of recent decades in immunodiagnostic techniques have enabled the development of methods capable of detecting the antigen-antibody complex with high efficiency and reliability. However, the cost of such procedures has remained high; they are not easy to handle for an unskilled professional, nor provide immediate results for multiple samples. Precision Photonics Corporation (PPC), with m/Bio Inc. and in partnership with the University of San Diego (UCSD), USA, created an integrated circuit reader (Biochip Reader), which is low cost, fast and easy to handle, based on an optical systems and multiplex arrangements for the detection of biological multi-markers at the same time. This study aimed to evaluate the operation of the integrated circuit reader system (Biochip Reader), the protocols and the results of the multiplex tests for antibodies against HIV and HCV in partnership with the Federal University of Bahia (UFBA). We tested a total of 65 samples in the Biochip reader, and they showed 100% of sensitivity and specificity when compared to the results obtained by ELISA for HIV and HCV. Nevertheless, the protocols and the results obtained in Bahia presented slide instability, such as the formation of crystals and trehalose residues, unnecessary steps and manipulation of the slides. This fact led to changing the protocol and improving the prototype. However, more tests with new biomarkers are needed to validate the method.","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132704297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mosquito ZeroTM","authors":"Alex Sandro Correia","doi":"10.34178/jbth.v2i1.53","DOIUrl":"https://doi.org/10.34178/jbth.v2i1.53","url":null,"abstract":"Mosquito Zero is an application that is designed to demonstrate the efficiency and effectiveness of information, education and communication between public authorities and citizens regarding Aedes aegypti, the diseases this mosquito transmits and the health impacts, providing citizens with a smooth and accessible channel of communication about the mosquito and arboviruses through the application and virtual robots.","PeriodicalId":103143,"journal":{"name":"JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122374020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}